$ALVR 90 DAYS STOCK PRICE FORECAST
Stock Price
About the Company
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
53
Company News
Analyzing AlloVir Inc.’s (ALVR) Stock Behavior
AlloVir Inc. (NASDAQ:ALVR) concluded the trading at $6.66 on Thursday, August 11 with a fall of -22.65% from its closing price on previous day. Taking a look at stock we notice that its last check on ...
Here’s Our Rant About AlloVir Inc. (ALVR)
AlloVir Inc. (NASDAQ:ALVR) went up by 13.96% from its latest closing price compared to the recent 1-year high of $26.41. The company’s stock price has collected 44.67% of gains in the last five ...
Research Analysts Issue Forecasts for AlloVir, Inc.’s FY2022 Earnings (NASDAQ:ALVR)
Stock analysts at SVB Leerink upped their FY2022 EPS estimates for AlloVir in a research report issued to clients and ...
AlloVir Reports Second Quarter 2022 Financial Results
“In the first half of 2022, AlloVir made great progress advancing our pipeline of off-the-shelf, multi-virus specific T cell therapies, especially with our lead candidate, posoleucel. The preliminary ...
Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
Shares of AlloVir, Inc. (ALVR) have gained 24.6% over the past four weeks to close the last trading session at $5.53, but there could still be a solid upside left in the stock if short-term price ...
Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares?
Every investor in AlloVir, Inc. (NASDAQ:ALVR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning ...
AlloVir (NASDAQ:ALVR) Price Target Cut to $23.00
AlloVir (NASDAQ:ALVR – Get Rating) had its price objective decreased by SVB Leerink from $30.00 to $23.00 in a research note ...
Research Analysts Issue Forecasts for AlloVir, Inc.’s FY2022 Earnings (NASDAQ:ALVR)
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) – Equities research analysts at SVB Leerink upped their FY2022 earnings estimates for shares of AlloVir in a report issued on Wednesday, July 27th.